BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
See today's BioWorld Asia
Home
» Advaxis kicks off global strategy in licensing deal with Taiwanese start-up
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Advaxis kicks off global strategy in licensing deal with Taiwanese start-up
Dec. 18, 2013
By
Shannon Ellis
No Comments
SHANGHAI – Advaxis Inc. signed an exclusive licensing agreement with newly minted Global Biopharma Inc. (GBP), of Taiwan, to develop and commercialize ADXH-HPV, an immunotherapy treatment for human papillomavirus (HPV) associated diseases.
BioWorld Asia